Effective contact rate for HSV-2 infection | βI | 0.2 | [1, 25] |
Effective contact rate for HIV infection | βH | 0.3 (0.11-0.95) | [30] |
Rate of acute HSV-2 becoming latent | κ1 | 2.3805(2.083-2.678) | [26] |
Rate of acute HSV-2 and HIV infected becoming latent | κ2 | 1.683(1.458-1.875) | [26] |
Treatment quitting rate | δ1 | 0.3 | [26, 27] |
Treatment quitting rate (dually infected) | δ2 | 0.3 | Assumed |
Proportion of HSV-2 patients who successfully complete treatment | θ1 | 0.7(0-1) | Assumed |
Proportion of patients who successfully complete treatment (dually infected) | θ2 | 0.8(0-1) | Assumed |
Reactivation rate with an effect of treatment (HSV-2 only) | γ(1)(ψ) | Varies | [1] |
Reactivation rate with an effect of treatment (dually infected) | γ(2)(ψ) | Varies | [1] |
Baseline reactivation rate of latent HSV-2 | $\begin{array}{}
\gamma_0^{(1)}
\end{array} $(ψ) | 0.339-0.436 | [26] |
Baseline reactivation rate of latent HSV-2 (dually infected) | $\begin{array}{}
\gamma_0^{(2)}
\end{array} $(ψ) | 0.365-0.469 | [26] |
Enhanced susceptibility of people with acute HSV-2 to HIV infection | σ | 2.7-3.1 | [29] |
Enhanced susceptibility to HSV-2 infection by HIV infectives | φ | ≥ 1 | [1] |
Treatment rate of acute HSV-2 | ψ | Varied | [1] |
Rate of progression from HIV to AIDS | ϕ | 0.0104 | [26] |
Average sexual lifespan | μ | 0.004(0.003-0.005) | [25, 26] |
AIDS-related death rate | v | 0.03 | [32] |
Modification parameter | α1 | (0−1) | Assumed |
Modification parameter | α2 | (0−1) | Assumed |
Modification parameter | η1 | (0−1) | Assumed |
Modification parameter | η2 | (0−1) | Assumed |
Modification parameter | τ | (0−1) | Assumed |